SCHEMBL425544

SCHEMBL425544

COc1ccc(N(C)C(=O)n2cnc(-c3ccccc3)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.52
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
ALOX12 P18054 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ACHE P22303 1/20 0.44
LIPE Q05469 1/20 0.44
PHGDH O43175 1/20 0.44
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
TMIGD3 P0DMS9 3/20 0.43
ADORA3 P0DMS8 2/20 0.43
HSP90AA1 P07900 1/20 0.42
PDK1 Q15118 1/20 0.42
PDK2 Q15119 1/20 0.42
PDK3 Q15120 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426694 0.95 ACHE (0.49) FAAHALDH1A1CYP3A4CYP2C9ALOX12
SCHEMBL425399 0.90 RAB9A (0.43) FAAHALDH1A1CYP3A4CYP2C9ALOX12
SCHEMBL425409 0.89 HSD17B2 (0.50) FAAHALDH1A1TP53MAPT
SCHEMBL425371 0.88 FAAH (0.60) FAAHACHELIPETP53
SCHEMBL425556 0.88 L3MBTL1 (0.43) FAAHACHELIPETP53POLB
SCHEMBL427476 0.85 FAAH (0.57) FAAHACHELIPETP53
SCHEMBL426698 0.81 FAAH (0.52) FAAHACHELIPETP53POLB
SCHEMBL425420 0.80 FAAH (0.52) FAAH
SCHEMBL426080 0.80 FAAH (0.52) FAAHCYP3A4CYP2C9CYP2C19HTT
SCHEMBL425535 0.80 FAAH (0.49) FAAHACHELIPETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885ALDH1A1 294/4885CYP3A4 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.